Clinical Trials

SLO Oncology & Hematology Health Center is affiliated with the UCLA Jonsson Comprehensive Cancer Center and UCLA's Translational Oncology Research International network. Furthering our commitment to bringing the most advanced cancer care available to our patients locally, we are pleased to announce SLO Oncology & Hematology Health Center is now affiliated with Stanford University Cancer Institute and the Eastern Cooperative Oncology Group (ECOG) of the National Cancer Institute (NCI). In combination with our continuing strong affiliation with UCLA, this will bring the most promising cancer treatments and most important clinical trials in the country right here to our local community, without the need for travel a long way from home. Our Private Investigator Dr. Brian DiCarlo, will work closely with our physicians and Clinical Research Coordinators, Amy and Lee, to determine patient eligibility for open clinical trials here at SLO Oncology & Hematology Health Center.  Our goal is to bring the most cutting-edge and advanced cancer treatments in the country right here to our local community without the need to travel.

Combining the UCLA research network with Stanford and ECOG fulfills the vision of a clinical trial portfolio with enough depth to give the opportunity for the majority of cancer patients to be offered a clinical trial in the community practice setting.

    

Watch Video:

Entering a Clinical Trial: Is it Right for You? (Dana-Farber Cancer Institute)

Clinical Trials Available

Bladder
Enrollment Status Description
Open

Roche 30070

A Phase III, Multicenter, Randomized, Placebo-Controlled, Partially Blinded Study Of Atezolizumab (Anti-Pd-L1 Antibody) Monotherapy And In Combination With Platinum-Based Chemotherapy Versus Platinum-Based Chemotherapy Alone In Patients With Untreated Locally Advanced Or Metastatic Urothelial Carcinoma

Open

Roche WO29636

A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection.

Breast
Enrollment Status Description
Open

SWOG 1418

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy.

Open

SWOG S1207

A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Theraphy +\- One Year of Everolimus in Pts w High Risk, Hormone Receptor-Postive and HER2/neu Negative Breast Cancer

Open

Syndax

A randomized, Placebo-Controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab with or without Entinostat in Patients with advanced Triple negative breast cancer, with a phase 1b lead in phase

Open

Takeda

An Open-Label Phase 2 Study of MLN0128 (A TORC1/2Inhibitor) in Combination With Fulvestrant in Women With ERPositive/
HER2-Negative Advanced or Metastatic Breast Cancer

Head & Neck
Enrollment Status Description
Open

BMS 714

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Hodgkins Lymphmoa
Enrollment Status Description
Open

BMS 655

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices.

Lung [NSCLC]
Enrollment Status Description
Open

ALCHEMIST

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

  • Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
  • A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
  • Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Open

BMS 370 (Checkmate)

A Phase 1 / 2 Studies of Nivolumab in Advanced NSCL using Nivolumab as First Line Treatment Alone or in Combination with Standard of Care Therapies.  (EGFR Mutatated patients only)

Open

POSEIDON

A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non-Small-Cell Lung Cancer (NSCLC)

Multiple Malignancies
Enrollment Status Description
Open

BMS 627

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies

Multiple Myeloma
Enrollment Status Description
Open

BMS 602

An Open-Label, Randomized Phase 3 Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma.

Ovarian
Enrollment Status Description
Open

NRG-GY004

A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

Open

NRG-GY005

A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)

Pancreatic
Enrollment Status Description
Open

ARMO AM0010-301

Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Meta Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen.

Open

Halo

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma.

Renal
Enrollment Status Description
Open

BMS 920

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Clinical Trial Resources

*Click the images to visit the websites!*